These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 1801540

  • 1. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Acta Neurol Scand Suppl; 1991; 136():70-2. PubMed ID: 1801540
    [Abstract] [Full Text] [Related]

  • 2. Selegiline as initial treatment in de novo parkinsonian patients.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Neurology; 1992 Feb; 42(2):339-43. PubMed ID: 1736162
    [Abstract] [Full Text] [Related]

  • 3. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
    Allain H, Pollak P, Neukirch HC.
    Mov Disord; 1993 Feb; 8 Suppl 1():S36-40. PubMed ID: 8302306
    [Abstract] [Full Text] [Related]

  • 4. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I.
    Eur Neurol; 1992 Feb; 32 Suppl 1():46-53. PubMed ID: 1425820
    [Abstract] [Full Text] [Related]

  • 5. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).
    Allain H, Cougnard J, Neukirch HC.
    Acta Neurol Scand Suppl; 1991 Feb; 136():73-8. PubMed ID: 1801541
    [Abstract] [Full Text] [Related]

  • 6. Selegiline in de novo parkinsonian patients: the Finnish study.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Mov Disord; 1993 Feb; 8 Suppl 1():S41-4. PubMed ID: 8302307
    [Abstract] [Full Text] [Related]

  • 7. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S, Heinonen EH, Hägglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J.
    Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
    [Abstract] [Full Text] [Related]

  • 8. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R, Swedish Parkinson Study Group.
    Neurology; 2006 Apr 25; 66(8):1200-6. PubMed ID: 16540603
    [Abstract] [Full Text] [Related]

  • 9. Selegiline as primary treatment in early phase Parkinson's disease--an interim report.
    Myllylä VV, Sotaniemi KA, Tuominen J, Heinonen EH.
    Acta Neurol Scand Suppl; 1989 Apr 25; 126():177-82. PubMed ID: 2515724
    [Abstract] [Full Text] [Related]

  • 10. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
    Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH.
    Acta Neurol Scand; 1997 Apr 25; 95(4):211-8. PubMed ID: 9150811
    [Abstract] [Full Text] [Related]

  • 11. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE.
    Mov Disord; 1998 Jul 25; 13(4):643-7. PubMed ID: 9686768
    [Abstract] [Full Text] [Related]

  • 12. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP, Boas J.
    Mov Disord; 1997 Mar 25; 12(2):175-82. PubMed ID: 9087975
    [Abstract] [Full Text] [Related]

  • 13. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B, Dupont E, Mikkelsen B, Mogensen P, Rasmussen C, Boesen F, Heinonen E.
    Acta Neurol Scand Suppl; 1989 Mar 25; 126():147-52. PubMed ID: 2515720
    [Abstract] [Full Text] [Related]

  • 14. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK.
    Neurology; 1998 Sep 25; 51(3):825-30. PubMed ID: 9748034
    [Abstract] [Full Text] [Related]

  • 15. A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.
    Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N.
    Clin Neuropharmacol; 2017 Sep 25; 40(5):201-207. PubMed ID: 28857772
    [Abstract] [Full Text] [Related]

  • 16. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
    Myllylä VV, Heinonen EH, Vuorinen JA, Kilkku OI, Sotaniemi KA.
    Acta Neurol Scand; 1995 Mar 25; 91(3):177-82. PubMed ID: 7793231
    [Abstract] [Full Text] [Related]

  • 17. Role of selegiline as initial monotherapy in early Parkinson's disease.
    Bhatia M, Jain S, Maheshwari MC.
    J Assoc Physicians India; 1994 Jan 25; 42(1):30-2. PubMed ID: 7836244
    [Abstract] [Full Text] [Related]

  • 18. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group.
    Shults CW.
    Acta Neurol Scand Suppl; 1993 Jan 25; 146():36-42. PubMed ID: 8333252
    [Abstract] [Full Text] [Related]

  • 19. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group.
    Larsen JP, Boas J, Erdal JE.
    Eur J Neurol; 1999 Sep 25; 6(5):539-47. PubMed ID: 10457386
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 25; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.